Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, de Boeck G, Maes RA, de Bruijn EA, van Oosterom A. Dumez H, et al. Among authors: assadourian s. Ann Oncol. 2006 Jul;17(7):1158-65. doi: 10.1093/annonc/mdl071. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600980 Free article. Clinical Trial.
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Vassal G, Couanet D, Stockdale E, Geoffray A, Geoerger B, Orbach D, Pichon F, Gentet JC, Picton S, Bergeron C, Cisar L, Assadourian S, Morland B; French Society of Pediatric Oncology; United Kingdom Children's Cancer Study Group. Vassal G, et al. Among authors: assadourian s. J Clin Oncol. 2007 Feb 1;25(4):356-61. doi: 10.1200/JCO.2006.06.1960. J Clin Oncol. 2007. PMID: 17264330 Clinical Trial.
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA. Bahleda R, et al. Among authors: assadourian s. Oncology. 2016;90(1):10-20. doi: 10.1159/000440958. Epub 2015 Oct 23. Oncology. 2016. PMID: 26492090 Clinical Trial.
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Ajani JA, et al. Among authors: assadourian s. J Clin Oncol. 2005 Aug 20;23(24):5660-7. doi: 10.1200/JCO.2005.17.376. J Clin Oncol. 2005. PMID: 16110025 Clinical Trial.
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: assadourian s. J Clin Oncol. 2005 Feb 1;23(4):889-98. doi: 10.1200/JCO.2005.01.008. J Clin Oncol. 2005. PMID: 15681535 Clinical Trial.
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Khayat D, Tejpar S, Spano JP, Verslype C, Bloch J, Vandecaveye V, Assadourian S, Soussan-Lazard K, Cartot-Coton S, Van Cutsem E. Khayat D, et al. Among authors: assadourian s. Eur J Cancer. 2013 Mar;49(4):790-7. doi: 10.1016/j.ejca.2012.10.012. Epub 2013 Jan 10. Eur J Cancer. 2013. PMID: 23312881 Clinical Trial.
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH. Schoemaker NE, et al. Among authors: assadourian s. Cancer Chemother Pharmacol. 2005 Mar;55(3):263-70. doi: 10.1007/s00280-004-0874-2. Epub 2004 Nov 16. Cancer Chemother Pharmacol. 2005. PMID: 15592838 Clinical Trial.
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Van Cutsem E, Khayat D, Verslype C, Billemont B, Tejpar S, Meric JB, Soussan-Lazard K, Assadourian S, Cartot-Cotton S, Rixe O. Van Cutsem E, et al. Among authors: assadourian s. Eur J Cancer. 2013 Jan;49(1):17-24. doi: 10.1016/j.ejca.2012.07.007. Epub 2012 Aug 24. Eur J Cancer. 2013. PMID: 22921183 Clinical Trial.
23 results